Sirius Medical, a medical device innovator developing the next generation of tumor localization technology, is pleased to announce today that the Mermaid Medical Group will be the exclusive distributor of Sirius Pintuition for the Nordic countries. Mermaid is a key experienced medical device distributor and manufacturer with a large product portfolio in the mammography and the oncology field. Sirius Pintuition has natural synergy with their product portfolio. Our aim is to collaborate with Mermaid and bring our novel system to the Nordic countries.
”This collaboration marks another important moment for Sirius”, says Bram Schermers, CEO and co-founder of Sirius Medical, “Mermaid Medical is a key player in the Nordic surgical oncology field and together, we will enable even wider access for patients and clinicians to Sirius Pintuition, our innovative tumor localization technology platform.”
‘’We have been committed to support the improvement of breast cancer treatment and care since 2012 and we are excited to see the clinical and economic benefits of Sirius Pintuition provided to patients and physicians.’’ says Lars Vinther, CEO of Mermaid Medical Group.
About Mermaid Medical
Mermaid Medical Group is a privately owned company established in 2007 devoted to developing, manufacturing, and distributing medical devices to hospitals and end users across Europe, the U.S., and Asia. Mermaid Medical primarily works within solutions to diseases in the vascular system as well as other devices used in interventional radiology and strive to be the preferred partner for manufacturers as well as hospitals and healthcare professionals in order to help patients across the world. For more information, visit www.mermaidmedical.com
About Sirius Medical
With its roots in the Netherlands Cancer Institute, Sirius Medical was born to make things better. The Sirius Pintuition system was developed by and for surgeons addressing a clear clinical need with a solution that simply makes sense. The Sirius Pintuition system is CE marked and received FDA clearance and is currently commercially available in Western Europe. Our mission is to improve care for cancer patients by delivering unsurpassed, yet affordable solutions that enable precise and efficient surgical removal of tumors.
For more information please contact:
Benjamin Tchang, Marketing manager